ATOS Stock

Is Atossa Therapeutics (ATOS) Stock Worth Buying In August 2021?

Atossa Therapeutics (NASDAQ:ATOS) stock experienced a roller coaster growth in June. The stock still lost 37% in its price in the past month despite a series of positive news from the company in June. So, is there a reason to buy the stock now? - August 09, 2021

Is Atossa Therapeutics (ATOS) Stock Worth To Buy?

Atossa Therapeutics (NASDAQ: ATOS) stock recorded a new high for the year a few days ago. In fact, the stock continued to grow since the company released its first quarter 2021 financial results on May 14th. The reason investors were so excited is the company has made great progress on its two key development programs. - June 15, 2021

Is Atossa Therapeutics (ATOS) Stock Worth To Buy?

Atossa Therapeutics (NASDAQ: ATOS) stock rose by 205% so far this year. The company said in its financial results for the first quarter of 2021 released on Friday that it has decided to withdraw from consideration the proposal to increase authorized shares of common stock by 325 million, and it has gained some positive results on its two key development drugs, which caused its stock to grow greatly 23% on that day. - May 15, 2021

Will Atossa Therapeutics (ATOS) Stock Continue To Rise After Soared 32% In A Week?

Atossa Therapeutics (NASDAQ: ATOS) stock soared by 32% over the past five trading days. Although the stock is still a penny stock, I am bullish on the stock's future. The company is a clinical-stage biopharmaceutical company and is focusing on breast cancer and COVID-19, and if it succeeds, its stock price will soar. - May 02, 2021

Atossa Therapeutics Has a Covid-19 Connection and Much More

It's fine to own ATOS stock based on the Covid-19 angle, but a broader view of the company reveals a commitment to under-treated conditions. - March 01, 2021

Why Kratos Defense & Security Solutions Stock Was Down Today | The Motley Fool

After an impressive run higher, one analyst is moving to the sidelines. - February 18, 2021

Why Atossa Therapeutics Stock Soared Today | The Motley Fool

Investors are excited about the potential of the biotech's experimental breast cancer treatment. - February 04, 2021